Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Next news (other than Ebola) will be the results of the CTE study currently conducted with Boston Univ CTE Center. There may also be updates on the FDA study when enrollment is complete and study is underway
Thanks for posting this, looks like you get what's happening here unlike our resident basher
Calling CTSO the competition is a stretch to say the least.
What they have to offer is cutting-edge software in a product in one of the hottest segments in the market, and they are going to be displaying it at the largest trade show for consumer electronics, CES 2015 in Las Vegas, in less than a month.
Your bashing is transparent, we know what your motives are.
Golly thanks for the warning! You must be a swell individual to come here and take the time and effort to warn us without anything to gain from doing so. You are truly one altruistic feller!
Shorts are market makers trying to keep a lid on the price
Dude it's at CES 2015, not a "test show"...are u for real or just making negative stuff up to try to get some shares back?
Ha considering you sold 50k at .63 just three days ago I'm sure you hoping for a flush out bwahaha lmao
Thanks for the cheap shares Adam!!
Nice efforts Charles
Now that's psycho-babble if I ever heard it
You sound extremely naiive--you should sell and go buy an index ETF
Logical that our product would be on hand in each of these.
http://www.chron.com/news/texas/article/Officials-designate-35-hospitals-for-Ebola-care-5929690.php
35 EBOLA-DESIGNATED U.S. HOSPITALS LISTED - Are You Near One?
Officials designate 35 hospitals for Ebola care
By MIKE STOBBE, AP Medical Writer
December 2, 2014 | Updated: December 3, 2014 12:09pm
NEW YORK (AP) — Health officials have designated 35 hospitals across the country as Ebola treatment centers. The U.S. Department of Health and Human Services released the list of hospitals on Tuesday. Most are clustered in metropolitan areas like New York City, San Francisco, Minneapolis and Washington D.C.
For more than a month, health officials have been talking to — and evaluating —hospitals that could serve as referral treatment centers for new Ebola cases that might occur. A team from the Centers for Disease Control and Prevention assessed more than 50 hospitals in 15 states and Washington, federal officials said.
The 35 hospitals are deemed to have the staff, equipment and training to safely and effectively care for Ebola, the government said. More hospitals will be added over the next several weeks to provide wider geographic coverage, officials said.
West Africa is currently suffering the worst Ebola outbreak in history, with more than 17,100 illnesses and at least 6,000 deaths so far. Four cases have been diagnosed in the United States.
The designated hospitals are:
Kaiser Oakland Medical Center, Oakland, California.
Kaiser South Sacramento Medical Center, Sacramento, California.
University of California Davis Medical Center, Sacramento, California.
University of California San Francisco Medical Center, San Francisco.
Emory University Hospital, Atlanta.
Ann & Robert H. Lurie Children's Hospital of Chicago.
Northwestern Memorial Hospital, Chicago.
Rush University Medical Center, Chicago.
University of Chicago Medical Center, Chicago.
Johns Hopkins Hospital, Baltimore.
University of Maryland Medical Center, Baltimore.
National Institutes of Health Clinical Center, Bethesda, Maryland.
Allina Health's Unity Hospital, Fridley, Minnesota.
Children's Hospitals and Clinics of Minnesota, St. Paul, Minnesota.
Mayo Clinic Hospital, Rochester, Minnesota.
University of Minnesota Medical Center, Minneapolis.
Nebraska Medical Center, Omaha.
Robert Wood Johnson University Hospital, New Brunswick, New Jersey.
North Shore System LIJ/Glen Cove Hospital, Glen Cove, New York.
Montefiore Medical Center, New York.
New York-Presbyterian/Allen Hospital, New York.
Bellevue Hospital Center, New York.
The Mount Sinai Hospital, New York.
Children's Hospital of Philadelphia, Philadelphia.
Hospital of the University of Pennsylvania, Philadelphia.
University of Texas Medical Branch at Galveston, Texas.
Methodist Richardson Medical Center, Richardson, Texas.
University of Virginia Medical Center, Charlottesville, Virginia.
Virginia Commonwealth University Medical Center, Richmond, Virginia.
Children's Hospital of Wisconsin, Milwaukee, Wisconsin.
Froedtert Hospital, Milwaukee, Wisconsin.
University of Wisconsin Hospital, Madison, Wisconsin.
MedStar Washington Hospital Center, Washington, D.C.
Children's National Medical Center, Washington, D.C.
George Washington University Hospital, Washington, D.C.
Oh I'm sorry you had to spend some time figuring out the connection...let me get my baby spoon out for you
This is a condition Aethlon through its subsidiary Exosome Sciences is developing a method for detection in living individuals...
Chronic Traumatic Encephalopathy (CTE) is a progressive degenerative disease of the brain found in athletes (and others) with a history of repetitive brain trauma. This trauma, which includes multiple concussions, triggers progressive degeneration of the brain tissue, including the build-up of an abnormal protein called tau. These changes in the brain can begin months, years, or even decades after the last concussion or end of active athletic involvement. The brain degeneration is associated with memory loss, confusion, impaired judgment, paranoia, impulse control problems, aggression, depression, and, eventually, progressive dementia.
CTE can only be definitively diagnosed through post-mortem examination of the brain, although efforts are underway to learn how to diagnose CTE in living people, a key step to developing a treatment for the disease.
CTE at a glance
First called “punch drunk” syndrome and dementia pugilistica, CTE was first described in 1928 by New Jersey pathologist Harrison Martland in “Martland HS: Punch drunk. JAMA 91:1103–1107, 1928” in which he noted symptoms such as slowed movement, tremors, confusion, and speech problems typical of the condition. In 1973, a group led by J.A. Corsellis described the typical neuropathological findings of CTE after post-mortem examinations of the brains of 15 former boxers.
The term “Chronic Traumatic Encephalopathy” appears in the medical literature as early as 1966 and is now the preferred term. Through 2009 there were only 49 cases described in all medical literature since 1928, 39 of whom were boxers. Many thought this was a disease exclusive to boxers, although cases have been identified in a battered wife, an epileptic, two mentally challenged individuals with head-banging behavior, and an Australian circus performer who was also involved in what the medical report authors referred to as “dwarf-throwing.”
CTE was not well known in sports outside of boxing until a Pittsburgh medical examiner named Bennet Omalu identified CTE in two former Pittsburgh Steelers who died in his jurisdiction in 2002 and 2005 and published his findings in two case reports. The work drew the attention of SLI co-founder Chris Nowinski as we was writing Head Games: Football’s Concussion Crisis, and he began reaching out to families of recently deceased former athletes to accelerate the work. He coordinated three more cases in 2006 and 2007 that Dr. Omalu and others diagnosed with CTE, including SLI’s first case, former WWE wrestler Chris Benoit.
In 2008 Nowinski and Dr. Robert Cantu, another co-founder of SLI, partnered SLI with Boston University School of Medicine to create the Center for the Study of Traumatic Encephalopathy (BU CSTE), the world’s first research center dedicated to studying CTE. In 2009, BU Professor Ann McKee, MD, a neuropathologist and one of the world’s foremost neurodegenerative disease experts, published the seminal paper on all known cases of CTE ever identified in the medical literature, adding three new cases from the BU CSTE to bring the total to 52.
Today, SLI and BU have created the world’s largest CTE repository, with over 100 diagnosed cases and over 170 brains of former athletes and military veterans. The brain bank contains more cases of CTE than the rest of the world, combined, throughout history, and the discoveries have redefined what we know about the disease.
Learn more about the most recent CTE findings, which were discussed at the first conference dedicated exclusively to CTE, here
Just signed deal with Payflex Systems, a subsidiary of Aetna! To use their technology to set-up online merchant payment system...that is a big company they've become involved with--this is no fly-by-night.
CTE is back in the news headlines unfortunately with the recent suicide of the Ohio State football player...
Aside from Ebola follow-up treatments and start of Hep-C trials, don't forget we expect news from this in January...
Aethlon Medical and Exosome Sciences Announce Clinical Collaboration with Boston University CTE Center To Advance Diagnostic Candidate to Detect CTE in Former NFL Players
SAN DIEGO, PRINCETON, N.J. and BOSTON, Sept. 26, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that a clinical collaboration with the Boston University (BU) CTE Center has been established to advance a blood-based diagnostic candidate that could identify Chronic Traumatic Encephalopathy (CTE) in living individuals.
CTE is a progressive neurodegenerative disorder that has been found at autopsy in former National Football League (NFL) players. At present, CTE can only be diagnosed through postmortem autopsy. The BU CTE Center has been a leading CTE research center since the disease was first defined.
Aethlon Medical develops targeted therapeutic devices to address infectious disease, cancer and neurodegenerative disorders. ESI (Aethlon subsidiary) develops exosome-based solutions to diagnose and monitor cancer and neurodegenerative disorders. Earlier this year, Aethlon disclosed that ESI researchers had successfully isolated exosome-based biomarkers transporting tau protein across the blood-brain barrier and into the circulatory system. The hallmark of CTE is an excess of accumulation of tau in the brain.
In the study, ESI researchers are evaluating and defining exosome and exosomal tau populations in blood samples collected from participants enrolled in the DETECT (Diagnosing and Evaluating Traumatic Encephalopathy Using Clinical Tests) study, under the direction of Dr. Robert Stern, Director of Clinical Research at the BU CTE Center.
The DETECT study is the first research project on CTE ever funded by the National Institutes of Health (NIH), with support from the National Institute of Neurologic Diseases and Stroke (NINDS), the National Institute on Aging (NIA), and the National Institute of Child Health and Human Development (NICHD). The ultimate goal of the study is to develop methods, including blood-based tests, that could diagnose CTE during life. The study has enrolled former NFL players (ages 40-69) and same-age "control" athletes who played non-contact sports.
"Our colleagues at the CTE Center are premier thought leaders in the CTE field and have been instrumental in changing how the NFL and other high-risk sports respond to head trauma," stated Aethlon Medical CEO Jim Joyce, who also serves as Executive Chairman of ESI. "We are truly grateful for the opportunity to establish a blood-based test that could identify CTE in living individuals."
About CTE
Chronic Traumatic Encephalo
- See more at: http://www.exosomesciences.com/NewsList.aspx#sthash.YIh07tdd.dpuf
Google The Equity Group, not a scam IR group to get involved with a purported scam company
Lifelogger recently raised $250,000 at $.60/share--can't believe somebody put up this cash at this price for a scam
Company will be showing device and demonstrating software at Consumer Electronics Show in 35 days in Las Vegas.
thanks for that info fried
Would think we have a nice ride here through CES at least
haha nice informational tickle...smart
Ok we are probably getting in to semantics, sounds like we're on the same page
Davita Healthcare Partners is just such a company with the facilities and infrastructure in place to take full advantage of the hemopurifier...and they will get an intimate working knowledge of the device since they are administering our upcoming Hep-C trials!
I'll tell you, the response by the spokesperson at the Nebraska facility reminds me of the arrogance found in the comments by the doctors at the Emory hospital.
These doctors would rather risk people's lives than admit there is a device out there they are unaware of that could have saved the lives that they lost.
Sorry Einstein but dilution, as defined by more shares issued at a price below current market price, effects all calculations per share, including price. The difference is that price per share is effected by more than just the # of shares outstanding.
If this financing positively impacts the numerator in the equation, market value (and via its ability to finance the upcoming trials while remaining independent,I believe it does), then the dilution can in fact have a positive effect on share price, at the very least in the medium to long term.
I guess the spokeperson is behind the curve lol
There's no way James Joyce puts out this news release today unless it is legit--the guy doesn't play games.
Yes Devita is a logical candidate to make a strategic investment in our company and fund the trials through to FDA approval in the US
It's true that reverse stock splits usually result in a decrease in the price of the stock post-split. But it doesn't have to be this way.
Besides the 600 million shares outstanding, the stock price may have suffered recently from a mass exodus of shareholders from CTSO to Aethlon Medical (AEMD), a company with a device broadly similar to Cytosorbents' but used to treat different conditions and with a different technology.
AEMD's device, called the hemopurifier, was named last week to TIME magazine's BEST INVENTIONS of 2014.
Cytosorbents' product is having good commercial success so far in Europe and India and may be a good buy around .17 or so.
Moderators, can you make a sticky out of the Time magazine award please?
Who is that and what do you think that means?
Look closely at Davita Health Partners...this is the New York stock exchange company which Warren Buffet owns millions of shares of...they are the company who is doing our Hep-C study that will commence any day now...they are among many candidates to make a strategic investment in AEMD (and infusion of substantial cash in return for a % of the company) which will end the need for AEMD to issue stock every quarter to raise cash. Once the share count is capped then the sky is the limit for the stock price.
This is all my opinion and speculation.
That's all you got Paulness? I'll let your post speak for itself.
Thy have successfully raised money year after year, in much leaner times, without being so close to frution. Get real dude, go back to your CTSO pumping and dreaming and hoping, and leave us alone
Or is it that you now want to buy AEMD but don't want to pay so much since you missed the boat? Or more likely you're here to volunteer your time and effort to help AEMD shareholders not lose their money.
Bwahahahahaha
Awesome BEAMBE is here! Wherever he bashes, the stock rises!!!
Congrats longs on your Beacon of Light Award!!!!
That and 20 cents will get you a share of CTSO lol